- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01334073
Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors (EVAX)
Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Phase I study of the combination of axitinib (AX) plus everolimus (EV) in patients with malignant advanced solid tumors.
- To determine the recommended dose for phase II study of the combination of AX + EV
- To determine the safety profile and predictive factors for toxicity, pharmacokinetics (PK), and efficacy in adult solid tumors.
- To assess functional vascular imaging (FVI) as surrogate marker of activity, biomarkers predictive of activity and preliminary efficacy data in metastatic RCC, untreated with antiangiogenics.
Phase I, multicentre, open-label, non-randomized, sequential algorithm based dose-finding (3+3), clinical study in successive cohorts of patients.
Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose (MTD; i.e. the DL at which <= 1/6 patient experiences a DLT during the first cycle). All decision concerning qualification for DLT, dose escalation, study termination, inclusion of additional patients, will be taken by a Trial Monitoring Committee..
The MTD will not be higher than the recommended dose of each single agent. Six additional patients will be entered at the MTD to confirm the feasibility of the dose and preliminarily assess the efficacy of the combination in patients with RCC untreated with antiangiogenics.
Three levels of dose will be explored.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Bordeaux, Frankrijk, 33000
- Professeur Alain RAVAUD
-
Toulouse, Frankrijk, 31000
- Professeur Jean-Pierre DELORD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria
- Histologically proven advanced adult solid tumors, with the exception of Hodgkin and non Hodgkin lymphoma. Patients with hepatocellular carcinomas (HCC) may be enrolled without histological documentation if they meet the consensus non-invasive diagnostic criteria.
- Failure or contra-indication of all standard therapies, except for the patients with advanced renal cell carcinoma, enrolled at the recommended dose who will be naïve of previous lines of therapy while metastatic.
- Age > 18 years
- ECOG Performance status (PS) 0-1
- Life expectancy > 3 months
- Measurable/evaluable disease according to RECIST CRITERIA version 1.0
- Acceptable biological values: Hemoglobin > 10g /dL; neutrophils > 1.5 x 109/L; platelets > 100 x 109/L, AST and ALT < 2.5 x the upper normal limits (UNL), or < 5 x UNL in case of liver metastases, GGT < 3 x the upper normal limits (UNL), PAL < 2.5 x the upper normal limits (UNL), or < 5 x UNL in case of liver metastases, serum bilirubin < 1.5 x ULN, creatinine clearance (Cockroft & Gault formula) > 60 mL/min.
- 24 hours proteinuria ≤ 1 g/24 h
- Albumin > 30 g/l
- Amylase and lipase ≤ 1.5 UNL
- Electrolytes (calcium, sodium, potassium, chlore, magnesium, phosphate) in the normal range. Supplementation could be possible before study entry.
- Total cholesterol ≤ 2.5 UNL
- Triglycerides ≤ 2.5 UNL
- BP < 140/90
- Washout period from last anticancer therapy, including radiation and surgery > 3 weeks and recovery of toxicities to NCI-CTC grade < 1.
- Written informed Consent.
- Use of effective contraceptive method (Intrauterine device, oral combined contraceptive) for women of child-bearing age or whose partner is included in the trial.
- Patient with french social security.
- Additional inclusion criteria before the association axitinib plus everolimus period
- No toxicity with NCI-CTC grade > 2 at the end of axitinib alone period just before starting axitinib and everolimus (cycle 1)
- BP < 140/ 90
Exclusion criteria
- Brain metastasis
- Severe underlying cardiovascular disease, even medically controlled, such as angina pectoris, myocardial infarction, cardiac insufficiency, cardiac failure, cerebral strokes, lower limb ischemic disease, thromboembolic disease, and any patient, who, in the investigator's opinion is at high risk for arterial or venous thromboembolism.
- Hepatitis B or C carrier or at a chronic state
- Uncontrolled hypertension, or diabetes mellitus despite medical treatment.
- Inability to swallow pills
- Unresolved pneumopathy, no need for antibiotherapy
- Any medical or social condition, which; in the investigator's opinion, would jeopardize patient's safety, patient's compliance to the protocol, or the interpretation of study results. These conditions include (but are not limited to): severe infection, cardiac failure, chronic gastrointestinal disease compromising oral drug absorption, psychiatric illnesses, foreseeable poor treatment compliance with oral medications, patients living far away from the investigational centers, etc…
- Hypersensitivity to Axitinib or Everolimus
- Participation to another clinical trial, or use of an unapproved medication within 4 weeks prior to study treatment initiation.
- Pregnant or lactating women.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Axitinib plus everolimus
|
Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day).
By convention one cycle is 28 days.
At the first cycle patients will take one week of AX single agent before starting EV.
Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Proportion of patients with DLT (dose limiting toxicity) during the first cycle (first 28 days of the combination of both study compounds), per dose level explored
Tijdsspanne: during cycle 1
|
A DLT will be one of the following adverse events, with a possible relationship to the study medications
|
during cycle 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Adverse event (AE) will be graded according to NCI-CTC criteria V3
Tijdsspanne: After each cycle of treatement
|
Number of AE per patient, per grade, per cycle and per dose level, proportion
|
After each cycle of treatement
|
Best response rate will be assessed according to RECIST criteria, during the follow-up
Tijdsspanne: Every other cycle of treatment
|
Frequency (total, per dose level), proportion
|
Every other cycle of treatment
|
Rate of non-tumor progression at 16 weeks
Tijdsspanne: at 16 weeks
|
Frequency (total, per dose level), proportion
|
at 16 weeks
|
Progression-free Survival (PFS) defined as the time between study treatment initiation and either tumor progression or death, regardless of the cause, whichever occurs first and PFS at 1 year
Tijdsspanne: 1 year
|
Frequency (total, per dose level), probability
|
1 year
|
Comparison of PK parameters
Tijdsspanne: day 1 (axitinib alone) and day 15 (everolimus combined with axitinib)
|
Plasma PK using peak concentration (Cmax), area under the concentration versus time curve (AUC), volume of distribution at steady state (Vdss), plasma clearance (CL) and plasma half-life (t1/2).
PK parameters will be compared to severe (grade 3-4) AEs, tumor responses and non-tumor progression at 16 weeks.
PK parameters of axitinib combined to everolimus (day 15) will be compared to PK parameters of axitinib alone in the same patient (day 1).
PK of everolimus combined to axitinib (day 15) will be compared to historical data of everolimus alone
|
day 1 (axitinib alone) and day 15 (everolimus combined with axitinib)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Alain RAVAUD, University Hospital, Bordeaux
Publicaties en nuttige links
Algemene publicaties
- Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res. 2010 Jan 1;16(1):348-57. doi: 10.1158/1078-0432.CCR-09-2087. Epub 2009 Dec 22.
- O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model. Cancer Chemother Pharmacol. 2011 Jan;67(1):193-200. doi: 10.1007/s00280-010-1307-z. Epub 2010 May 30.
- Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008 Jun;9(6):658-71.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Urologische neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Nier Ziekten
- Urologische ziekten
- Adenocarcinoom
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Nierneoplasmata
- Carcinoom, niercel
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Proteïnekinaseremmers
- Axitinib
- Everolimus
Andere studie-ID-nummers
- CHUBX 2010/09
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Carcinoom, niercel
-
Peking University People's HospitalOnbekendNatural Killer Cell-gemedieerde immuniteitChina
-
Postgraduate Institute of Medical Education and...VoltooidType 1 HEPATO RENAL SYNDROOM (HRS)Indië
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisActief, niet wervendRefractaire Hurthle Cell-schildklierkankerVerenigde Staten
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
Hadassah Medical OrganizationOnbekendNatural Killer Cell-deficiëntie, familiaal geïsoleerdIsraël
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
Assistance Publique - Hôpitaux de ParisNog niet aan het werven
-
Bing HanVoltooidPure Red Cell Aplasia, verworvenChina
-
Peking University First HospitalWervingNiercelcarcinoom, Clear Cell, SomatischChina
-
National Institute of Diabetes and Digestive and...WervingSchildklierkanker | Papillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkankerVerenigde Staten
Klinische onderzoeken op Axitinib plus everolimus
-
Hospital of MacerataWerving
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.WervingHepatobiliair neoplasma | Lever neoplasma | Neoplasmata van de galwegenChina
-
ZHOU FANGJIANPfizerWervingNiercelcarcinoom | NeoadjuvantChina
-
Bart NeynsPfizerVoltooid
-
Hutchison Medipharma LimitedWervingGeavanceerd niercelcarcinoomChina
-
PfizerIngetrokkenCarcinoom, niercel | Glioblastoom | Carcinoom, hepatocellulair
-
Shanghai Pulmonary Hospital, Shanghai, ChinaWerving
-
National Taiwan University HospitalNovartisOnbekendUitgezaaide borstkankerTaiwan
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Actief, niet wervendGoed gedifferentieerde endocriene pancreastumorItalië
-
West China HospitalActief, niet wervendCarcinoom, niercel | Immunotherapie | Fumaraathydratase-deficiëntieChina